TY - JOUR
T1 - The validity and utility of the M. D. Anderson symptom inventory in patients with breast cancer
T2 - Evidence from the symptom outcomes and practice patterns data from the eastern cooperative oncology group
AU - Mendoza, Tito R.
AU - Zhao, Fengmin
AU - Cleeland, Charles S.
AU - Wagner, Lynne I.
AU - Patrick-Miller, Linda J.
AU - Fisch, Michael J.
N1 - Funding Information:
We thank Jeanie F. Woodruff, ELS, for editorial assistance and the ECOG Symptom Outcomes and Practice Patterns study for the data. This study was supported in part by grants to ECOG from the National Cancer Institute of the National Institutes of Health, including U10 CA37403, U10 CA17145, and U10 CA107868. Additional support comes from R01 CA026582 to C.S.C and MD Anderson Cancer Center Support Grant P30 CA016672 to R. A. DePinho. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
PY - 2013/10
Y1 - 2013/10
N2 - Background: The M. D. Anderson Symptom Inventory (MDASI) is a psychometrically validated patient-reported outcome measurement that assesses the severity and impact of multiple symptoms related to cancer and its treatment. With the MDASI, patients rate 13 common "core" symptoms and 6 items that reflect symptom interference with functioning. Several MDASI modules (core symptom and interference items plus additional symptoms specific to a particular cancer type or treatment modality) have been developed. Although the original MDASI validation study encompassed various cancer types, the instrument's psychometric properties have not been examined in a homogenous sample of patients with breast cancer in a national multicenter study. Materials and Methods: We performed a secondary analysis of data from an Eastern Cooperative Oncology Group study to establish the reliability, validity, and sensitivity of the MDASI in a large sample of patients with breast cancer (n = 1544), 78% of whom were receiving treatment. The instrument was administered twice, approximately 1 month apart. Results: Internal consistency and test-retest reliability were adequate, with Cronbach α values ≥ 0.85 and intraclass correlations ≥ 0.76 for all subscales. Known-group validity was evaluated by using performance status, tumor response, and disease stage. Sensitivity to change in patient-reported quality of life was established. Conclusion: The MDASI is a valid, reliable, and sensitive symptom-assessment instrument that can enhance descriptive and clinical studies of symptom status in patients with breast cancer. Future studies might include cognitive debriefing and qualitative interviews to identify additional disease-specific items for inclusion in a MDASI breast cancer module.
AB - Background: The M. D. Anderson Symptom Inventory (MDASI) is a psychometrically validated patient-reported outcome measurement that assesses the severity and impact of multiple symptoms related to cancer and its treatment. With the MDASI, patients rate 13 common "core" symptoms and 6 items that reflect symptom interference with functioning. Several MDASI modules (core symptom and interference items plus additional symptoms specific to a particular cancer type or treatment modality) have been developed. Although the original MDASI validation study encompassed various cancer types, the instrument's psychometric properties have not been examined in a homogenous sample of patients with breast cancer in a national multicenter study. Materials and Methods: We performed a secondary analysis of data from an Eastern Cooperative Oncology Group study to establish the reliability, validity, and sensitivity of the MDASI in a large sample of patients with breast cancer (n = 1544), 78% of whom were receiving treatment. The instrument was administered twice, approximately 1 month apart. Results: Internal consistency and test-retest reliability were adequate, with Cronbach α values ≥ 0.85 and intraclass correlations ≥ 0.76 for all subscales. Known-group validity was evaluated by using performance status, tumor response, and disease stage. Sensitivity to change in patient-reported quality of life was established. Conclusion: The MDASI is a valid, reliable, and sensitive symptom-assessment instrument that can enhance descriptive and clinical studies of symptom status in patients with breast cancer. Future studies might include cognitive debriefing and qualitative interviews to identify additional disease-specific items for inclusion in a MDASI breast cancer module.
KW - Eastern Cooperative Oncology Group
KW - M. D. Anderson Symptom Inventory
KW - Patient-reported outcome
KW - Symptom assessment
KW - Validation
UR - http://www.scopus.com/inward/record.url?scp=84883805923&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883805923&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2013.02.014
DO - 10.1016/j.clbc.2013.02.014
M3 - Article
C2 - 23816985
AN - SCOPUS:84883805923
SN - 1526-8209
VL - 13
SP - 325
EP - 334
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 5
ER -